Wexford Capital’s Nurix Therapeutics NRIX Stock Holding History

Wexford Capital’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,487	Closed	-$41.5K	–	482
2025 Q3	$41.5K	Buy	+4,487	New	+$46.6K	0.01%	321

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wexford Capital's NRIX Position: Q4 2025 in Review

Wexford Capital sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 4,487 shares — an estimated $41.5K sold.

Wexford Capital first reported a position in NRIX in Q3 2025 and held it in 1 quarter. The position peaked at $41.5K in Q3 2025. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

Wexford Capital reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
Wexford Capital sold 4,487 Nurix Therapeutics shares in Q4 2025, an estimated $41.5K.
Wexford Capital first reported a position in Nurix Therapeutics in Q3 2025 and held it in 1 quarter.
Wexford Capital's Nurix Therapeutics position peaked at $41.5K in Q3 2025.
182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.